ABOUT

Boston based Haas and Partners Collaborates with a global network of experts in a broad range of disciplines.


Joanna-Haas-350“Client-oriented, practical solutions from first in man to post-approval safety and effectiveness.”

Joanna F Haas MD MSc, FACP, FACPM. FISPE

FOUNDING PARTNER, Haas and Partners LLC

CHIEF SCIENTIST, PHARMACOVIGILANCE 
OptumInsight Waltham, MA, USA
VICE PRESIDENT, GLOBAL PATIENT SAFETY AND RISK MANAGEMENT Genzyme Corporation Cambridge, MA, USA
EXECUTIVE MEDICAL DIRECTOR, Drug Safety and Epidemiology Novartis USA
GROUP DIRECTOR, GLOBAL PHARMACOVIGILANCE
 Rhone-Poulenc Paris, France
HEAD CORPORATE DRUG SAFETY
 Boehringer Ingelheim
 Ingelheim, Germany

Joanna F Haas founded Haas and Partners LLC to provide strategic client focused consulting services for benefit risk evaluation of medical therapeutics. The goal was to help companies define their pharmacovigilance and risk management needs and negotiate the myriad of services, products and tools offered.

Dr. Haas has held senior positions (clinical development, product safety and risk management) with leading biopharmaceutical companies in the EU (Immuno, Boehringer Ingelheim, Rhone-Poulenc-Rorer) and US (Novartis, Genzyme). Her work has covered a range of safety concerns including organ specific toxicities (e.g. cardiac, renal, hepatic), carcinogenicity, hypersensitivity and pregnancy exposure risk. Product experience includes pharmaceutical agents, biologic products and advanced therapeutics in a broad range of therapeutic settings (e.g. oncology, cardiovascular, renal and metabolic disorders, neurologic disease). She has worked with diverse international regulatory agencies to provide expert, evidence-based benefit-risk evaluation and management guidance.

An internationally recognized expert in risk management and pharmacoepidemiology, who holds board certification in internal medicine and in preventive medicine. She is a  Fellow of the American College of Physicians, the American College of Preventive Medicine and the International Society of Pharmacoepidemiology.

Languages
ENGLISH 
- native language
GERMAN 
and FRENCH – proficient
SPANISH – conversant
Education
BOSTON UNIVERSITY SCHOOL OF MEDICINE.
 BA and MD, 6-Year Program in Liberal Arts and Medicine
COLUMBIA UNIVERSITY MAILMAN SCHOOL OF PUBLIC HEALTH
 Master of Science, Epidemiology
MCGILL UNIVERSITY
 Diplome, Epidemiologie
UNIVERSITY OF CALIFORNIA, LOS ANGELES,
School of Public Health Post Doctoral Scholar
US Board Certifications in Internal Medicine and in Preventive Medicine
Honors & Awards
FELLOW OF THE AMERICAN COLLEGE OF PHYSICIANS (FACP)
FELLOW OF THE AMERICAN COLLEGE OF PREVENTIVE MEDICINE (FACPM)
FELLOW OF THE INTERNATIONAL SOCIETY OF PHARMACOEPIDEMIOLOGY (FISPE)
VISITING SCIENTIST
Harvard School of Public Health 
2010 – 2013


Benefit-Risk Management Strategy from a Global perspective, across life cycle stages, product genres, therapeutic areas and safety issues.